Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide

Bone Marrow Transplantation

Volumn 24, Issue 9, 1999, Pages 947-952

  Worth, L L ^a   Tran, H ^a   Petropoulos, D ^a   Culbert, S C ^a   Mullen, C A ^a   Roberts, W M ^a   Przepiorka, D ^a   Chan, K W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Busulfan; Cyclophosphamide; Hematopoietic stem cell transplantation; Myeloid malignancies; Thiotepa

Indexed keywords

BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GANCICLOVIR; IMMUNOGLOBULIN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; ESOPHAGITIS; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERPIGMENTATION; INFANT; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG HEMORRHAGE; MALE; MYELODYSPLASIA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SIBLING; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; VEIN OCCLUSION;

EID: 0032712290     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702016     Document Type: Article

References (30)

1. Wells RJ, Gold SH, Krill CE et al. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Leukemia 1994; 8: 1626-1630.
2. Gale RP, Horowitz MM, Rees JK et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996; 10: 13-19.
3. Brandwein JM, Horsman DE, Eaves AC, Eaves CJ et al. Childhood myelodysplasia: suggested classification as myelodysplastic syndromes based on laboratory and clinical findings. Am J Ped Hematol Oncol 1990; 12: 63-70.
4. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723-1729.
5. Long GD, Amylon MD, Stockerl-Goldstein KE et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3: 324-330.
6. Locatelli F, Zecca M, Niemeyer C et al. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. Bone Marrow Transplant 1996; 18 (Suppl. 2): 63-68.
7. Sanders JE. Bone marrow transplantation for pediatric malignancies. Pediatr Clin North Am 1997; 44: 1005-1020.
8. Hongeng S, Krance RA, Bowman LC et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-771.
9. Szydlo R, Goldman JM, Klein JP et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767-1777.
10. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
11. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
12. Davies SM, Wagner JE, Shu XO et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997; 15: 557-566.
13. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study. Blood 1993; 81: 2187-2193.
14. Michel G, Gluckman E, Esperou-Bourdeau H et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation - a report from the Société Française de Greffe de Moelle. J Clin Oncol 1994; 12: 1217-1222.
15. Aurer I, Gale RP. Are new conditioning regimens for transplants in acute myelogenous leukemia better? Bone Marrow Transplant 1991; 7: 255-261.
16. Brown RA, Wolff SN, Fay JW et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 1995; 85: 1391-1395.
17. Down JD, Westerhof GR, Boudewjin A. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transplant 1998; 21: 327-330.
18. Przepiorka D, Ippoliti C, Giralt S et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 1994; 14: 449-453.
19. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of granulocyte-stimulating-growth factor (filgastrim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges. Transfusion 1996; 36: 590-595.
20. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
21. Yam P, Petz LD, Ali S et al. Development of a single probe for documentation of chimerism following bone marrow transplantation. Am J Hum Genet 1987; 41: 867-881.
22. Przepiorka D, Weisdorf D, Martin P et al. (Meeting report). Consensus conferences on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-827.
23. Tran HT, Madden T, Felix E et al. Evaluations of a preparative regimen containing adjusted-dose busulfan with stem cell support for the treatment of advanced hematolgical malignancies in pediatric patients. Blood 1996; 10 (Suppl. 1): 260b.
24. Przepiorka D, Dimopoulos M, Smith T et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol 1994; 68: 183-188.
25. Dinndorf P, Bunin N. Bone marrow transplantation for children with acute myelogenous leukemia. J Pediatr Hematol Oncol 1995; 17: 211-224.
26. Schiller G, Feig SA, Territo M et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 1994; 88: 72-78.
27. Mehta J, Powles R, Horton C et al. Bone marrow transplantation for primary refractory acute leukemia. Bone Marrow Transplant 1994; 14: 415-418.
28. Przepiorka D, Ippoliti C, Khouri I et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation 1996; 62: 1806-1810.
29. Kernan NA. Graft failure following transplantation of T-cell depleted marrow. In: Burakoff SJ, Deeg HI, Ferrara J, Atkinson K (eds). Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. Marcel Dekker: New York, 1990, pp 557-568.
30. Woolfrey AE, Sanders JE. Bone marrow transplantation for children less than two years of age with acute myelogeneous leukemia or myelodysplastic syndrome. Exp Hematol 1998; 26: 691.